〇Katoh N, Tanaka A, Takahashi H, Shimizu R, Kataoka Y, Torisu-Itakura H, Morisaki Y, Igawa K. Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J). Curr Med Res Opin 2025; 41: 1-12. (2025)

 

〇Katoh N, Tanaka A, Takahashi H, Shimizu R, Kataoka Y, Torisu-Itakura H, Morisaki Y, Yamamoto C, Igawa K. Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week randomized double-blind placebo-controlled phase III trial in Japan (ADhere-J). Br J Dermatol. 2025; 192: 597-610. (2025)

 

〇Takagi T, Xu L, Hoshi M, Arai S. Identifying Risk Factors of Major Adverse Cardiac Events in Patients With Ulcerative Colitis: A Retrospective Japanese Claims Data Analysis. J Gastroenterol Hepatol. 2025 Feb;40(2):421-432. (2025)

 

〇Guttman-Yassky E, Katoh N, J Cork M, Jagdeo J, F Alexis A, Chen Z, A Levit N, B Rossi A. Dupilumab treatment improves lichenification in atopic dermatitis in different age and racial groups. J Drugs Dermatol. 2025; 24: 167-173. (2025)

 

〇Katoh N, Ikeda M, Ohya Y, Murota H, Hu X, Liu J, Niiyama H, Sasaki T, Raymundo EM, Saeki H. Safety and efficacy of upadacitinib for atopic dermatitis in Japan: analysis of the 3-year phase 3 Rising Up study. Dermatol Ther (Heidelb). 2024; 14: 213-232. (2024)

 

〇Yasuda T, Takagi T, Asaeda K, Hashimoto H, Kajiwara M, Azuma Y, Kitae H, Hirai Y, Mizushima K, Doi T, Inoue K, Dohi O, Yoshida N, Uchiyama K, Ishikawa T, Konishi H, Ukawa Y, Kohara A, Kudoh M, Inoue R, Naito Y, Itoh Y. Urolithin A-mediated augmentation of intestinal barrier function through elevated secretory mucin synthesis. Sci Rep. 2024 Jul 8;14(1):15706. (2024)

 

〇Hashimoto H, Takagi T, Asaeda K, Yasuda T, Kajiwara M, Sugaya T, Mizushima K, Inoue K, Uchiyama K, Kamada K, Higashimura Y, Inoue R, Naito Y, Itoh Y. D-alanine Inhibits Murine Intestinal Inflammation by Suppressing IL-12 and IL-23 Production in Macrophages. J Crohns Colitis. 2024 Jun 3;18(6):908-919.

 

〇Ueno M, Imai K, Tomioka Y, Horiguchi G, Kameda T, Teramukai S, Tsujikawa A, Inatomi T, Sotozono C, Kinoshita S. Comprehensive combined analysis of physician-initiated phase II and III clinical trials on a cultured human corneal endothelial cell product for treating bullous keratopathy. Jpn J Ophthalmol. 2024 Nov;68(6):660-668. (2024)

 

〇Takagi T, Kunihiro T, Takahashi S, Hisada T, Nagashima K, Mochizuki J, Mizushima K, Naito Y. A newly developed solution for the preservation of short-chain fatty acids, bile acids, and microbiota in fecal specimens. J Clin Biochem Nutr. 2023 May;72(3):263-269. (2023)

 

〇Tomida A, Chiyonobu T, Tokuda S, Miyachi M, Murashima K, Hirata M, Nakagawa M, Iehara T, Kuroda J, Takayama K. Pleomorphic rhabdomyosarcoma in a young adult harboring a novel germline MSH2 variant. Hum Genome Var. 2022 Mar 8;9(1):8. (2022)

 

〇Kinoshita S, Koizumi N, Ueno M, Okumura N, Imai K, Tanaka H, Yamamoto Y, Nakamura T, Inatomi T, Bush J, Toda M, Hagiya M, Yokota I, Teramukai S, Sotozono C, Hamuro J. Injection of Cultured Cells with a ROCK Inhibitor for Bullous Keratopathy. N Engl J Med. 2018 Mar 15;378(11):995-1003. (2018)

 

〇今井浩二郎. 再生医療の推進に向けて. 医療経済研究機構レター. No.223 Page29-36. (2013)